
Sino Biological/SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein/1/40588-V08B
商品编号:
40588-V08B
品牌:
sinobiological
市场价:
¥0.00
美元价:
0.00
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: Product Information
Purity
> 90 % as determined by SDS-PAGE.
Endotoxin
< 1.0="" eu="" per="" μg="" protein="" as="" determined="" by="" the="" lal="">
Activity
Testing in progress
Protein Construction
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein (YP_009724397.2(335Gly/Ala)) (Met1-Ala419) was expressed with a polyhistidine tag at the C-terminus.
Accession#
YP_009724397.2
Expressed Host
Baculovirus-Insect Cells
Species
2019-nCoV
Predicted N Terminal
Met 1
Molecule Mass
The recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein (His tag) consists of 430 amino acids and predicts a molecular mass of 47.08 kDa.
Formulation
Lyophilized from sterile 20mM Tris, 500mM NaCl, pH8.0, 10%glycerolPlease contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: Images

SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein: Synonyms
coronavirus NP Protein, 2019-nCoV; coronavirus Nucleocapsid Protein, 2019-nCoV; coronavirus Nucleoprotein Protein, 2019-nCoV; cov np Protein, 2019-nCoV; ncov NP Protein, 2019-nCoV; NCP-CoV Nucleocapsid Protein, 2019-nCoV; novel coronavirus NP Protein, 2019-nCoV; novel coronavirus Nucleocapsid Protein, 2019-nCoV; novel coronavirus Nucleoprotein Protein, 2019-nCoV; np Protein, 2019-nCoV; nucleocapsid Protein, 2019-nCoV; Nucleoprotein Protein, 2019-nCoV
Coronavirus Nucleocapsid Background Information
Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. The coronavirus N protein is required for coronavirus RNA synthesis and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is the most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to the formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of the N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.
References
- 1.Van Boheemen S, et al. (2012),MBio. 3(6):e00473-12.
- Bisht H. et al., 2004,Proc Natl Acad Sci. 101 (17): 6641-6.
- Li W. et al., 2005,Science.309 (5742): 1864-8.
2019-nCoV Coronavirus Nucleocapsid Proteins
- SARS-CoV-2 (2019-nCoV) Nucleocapsid-His Recombinant Protein40588-V07E
- SARS-CoV-2 (2019-nCoV) Nucleocapsid-His recombinant Protein, Biotinylated40588-V08B-B
- SARS-CoV-2 (2019-nCoV) Nucleocapsid-His Recombinant Protein, Biotinylated40588-V07E-B
- SARS-CoV-2 (2019-nCoV) Nucleocapsid-AVI & His recombinant Protein, Biotinylated40588-V27B-B
HCoV-OC43 Coronavirus Nucleocapsid Proteins
- Human coronavirus (HCoV-OC43) Nucleoprotein / NP Protein (His Tag)40643-V07E
HCoV-NL63 Coronavirus Nucleocapsid Proteins
- Human coronavirus (HCoV-NL63) Nucleoprotein / NP Protein (His Tag)40641-V07E
HCoV-229E Coronavirus Nucleocapsid Proteins
- Human coronavirus (HCoV-229E) Nucleoprotein / NP Protein (His Tag)40640-V07E
SARS Coronavirus Nucleocapsid Proteins
- SARS-CoV Nucleoprotein / NP Protein (His Tag)40143-V08B
HCoV-HKU1 Coronavirus Nucleocapsid Proteins
- Human coronavirus (HCoV-HKU1) Nucleoprotein / NP Protein (His Tag)40642-V07E
MERS-CoV Coronavirus Nucleocapsid Proteins
- MERS-CoV Nucleoprotein / NP protein (His Tag)40068-V08B
- Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen MicroarrayAuthorDe Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;Year2020JournalBioRxivFoldedExpand
- Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen MicroarrayAuthorKhan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;Year2020JournalBioRxivFoldedExpand
- COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in salivaAuthorRandad, PR;Pisanic, N;Kruczynski, K;Manabe, YC;Year2020JournalmedRxivFoldedExpand
- Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patientsAuthorSun, B;Feng, Y;Mo, X;Zheng, P;Wang, Q;Li, P;Peng, P;Liu, X;Chen, Z;Huang, H;Zhang, F;Luo, W;Niu, X;Hu, P;Wang, L;Peng, H;Huang, Z;Feng, L;Li, F;Zhang, F;Li, F;Zhong, N;Chen, L;Year2020JournalEmerg Microbes InfectPubMed ID: 32357808FoldedExpand
- SARS-CoV-2 Antibody responses do not predict COVID-19 disease severityAuthorPhipps, WS;SoRelle, JA;Li, QZ;Mahimainathan, L;Year2020JournalmedRxivApplicationIgM testingFoldedExpand
- Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infectionAuthorSimon, D;Tascilar, K;Krönk, G;Kleyer, A;Zaiss, M;Heppt, F;Meder, C;Atreya, R;Klenske, E;Dietrich, P;Abdullah, A;Kliem, T;Corte, G;Morf, H;Leppkes, M;Kremer, A;Ramming, A;Pachowsky, M;Schuch, F;Ronneberger, M;Kleinert, S;Maier, C;Hueber, A;Manger, K;Manger, B;Berking, C;Tenbusch, M;Überla, K;Sticherling, M;Neurath, M;Schett, G;Year2020JournalResearch SquareFoldedExpand
- SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patientsAuthorLei, H;Ye, F;Liu, X;Huang, Z;Ling, S;Jiang, Z;Cheng, J;Huang, X;Wu, Q;Wu, S;Xie, Y;Xiao, C;Ye, D;Yang, Z;Li, Y;Leung, NHL;Cowling, BJ;He, J;Wong, SS;Zanin, M;Year2020JournalInfluenza Other Respir VirusesPubMed ID: 32578948FoldedExpand
- SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalenceAuthorden Hartog, G;Schepp, R;Kuijer, M;GeurtsvanKessel, C;van Beek, J;Rots, N;Koopmans, M;van der Klis, F;van Binnendijk, R;Year2020JournalmedRxivFoldedExpand
- COVID-19 Severity Correlates with Weaker T Cell Immunity, Hypercytokinemia and Lung Epithelium InjuryAuthorWang, Z;Yang, X;Zhou, Y;Sun, J;Liu, X;Zhang, J;Mei, X;Zhong, J;Zhao, J;Ran, P;Year2020JournalAm. J. Respir. Crit. Care Med.Applicationneutralization testPubMed ID: 32608999FoldedExpand
- SARS-CoV-2 surveillance for a non-human primate breeding research facilityAuthorYee, JL;Van Rompay, KKA;Carpenter, AB;Nham, PB;Halley, BM;Iyer, SS;Hartigan-O"Connor, DJ;Miller, CJ;Roberts, JA;Year2020JournalJ. Med. Primatol.PubMed ID: 32621339FoldedExpand
- A rapidly adaptable biomaterial vaccine for SARS-CoV-2AuthorLangellotto, F;Seiler, B;Yu, J;Cartwright, M;White, D;Yeager, C;Super, M;Doherty, E;Barouch, D;Mooney, D;Year2020JournalbioRxivFoldedExpand
- Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19 immunityAuthorMcAndrews, KM;Dowlatshahi, DP;Dai, J;Becker, LM;Hensel, J;Snowden, LM;Leveille, JM;Brunner, MR;Holden, K;Hopkins, NS;Harris, A;Kumpati, JJ;Whitt, MA;Lee, JJ;Ostrosky-Zeichner, L;Papanna, R;LeBleu, V;Allison, J;Kalluri, R;Year2020JournalJCI InsightPubMed ID: 32796155FoldedExpand
- Accurate Serology for SARS-CoV-2 and common Human Coronaviruses using a Multiplex ApproachAuthorvan Tol, S;Mögling, R;Li, W;Godeke, GJ;Swart, A;Bergmans, B;Brandenburg, A;Kremer, K;Murk, JL;van Beek, J;Wintermans, B;Reimerink, J;Bosch, BJ;Reusken, C;Year2020JournalEmerg Microbes InfectPubMed ID: 32819220FoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
E.coli protein expression service
Mammalian transient protein expression service
Baculovirus-insect expression service
Stable cell line development service (CHO / HEK293)
品牌介绍
北京义翘神州科技股份有限公司(Sino Biological Inc.)是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司,主要业务包括重组蛋白、抗体、基因和培养基等产品,以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种,其中重组蛋白约 6,000 种,包括超过 3,800 种人源细胞表达重组蛋白产品,能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求;公司还能提供约 12,000 种抗体,其中单克隆抗体数量约 4,600 种,能够覆盖生命科学研究的多个领域,为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司,已成为生物试剂行业国内领先的科技公司之一。
联络我们